Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation: A Randomized, Open-Label, Pilot Intervention Trial

Trial Profile

Eculizumab Therapy for Chronic Complement-Mediated Injury in Kidney Transplantation: A Randomized, Open-Label, Pilot Intervention Trial

Completed
Phase of Trial: Phase I

Latest Information Update: 04 Oct 2016

At a glance

  • Drugs Eculizumab (Primary)
  • Indications Renal transplant rejection
  • Focus Therapeutic Use
  • Most Recent Events

    • 04 Oct 2016 New trial record
    • 08 Aug 2016 Status changed from active, no longer recruiting to completed, according to results published in the American Journal of Transplantation.
    • 08 Aug 2016 Primary endpoint (Percent change in GFR) has been met, according to results published in the American Journal of Transplantation.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top